141 related articles for article (PubMed ID: 36722141)
21. A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody-Drug Conjugates (ADCs).
Miller ML; Shizuka M; Wilhelm A; Salomon P; Reid EE; Lanieri L; Sikka S; Maloney EK; Harvey L; Qiu Q; Archer KE; Bai C; Vitharana D; Harris L; Singh R; Ponte JF; Yoder NC; Kovtun Y; Lai KC; Ab O; Pinkas J; Keating TA; Chari RVJ
Mol Cancer Ther; 2018 Mar; 17(3):650-660. PubMed ID: 29440292
[TBL] [Abstract][Full Text] [Related]
22. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers.
Gregson SJ; Barrett AM; Patel NV; Kang GD; Schiavone D; Sult E; Barry CS; Vijayakrishnan B; Adams LR; Masterson LA; D'Hooge F; Snaith M; Harper J; Hartley JA; Howard PW
Eur J Med Chem; 2019 Oct; 179():591-607. PubMed ID: 31279293
[TBL] [Abstract][Full Text] [Related]
24. ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies.
Zammarchi F; Havenith KE; Sachini N; Janghra N; Chivers S; Idusogie E; Gaudio E; Tarantelli C; Bertelli F; Santos K; Tyrer P; Corbett S; Spriano F; Golino G; Cascione L; Bertoni F; Hartley JA; van Berkel PH
Mol Cancer Ther; 2024 Apr; 23(4):520-531. PubMed ID: 38324336
[TBL] [Abstract][Full Text] [Related]
25. Engineering CD276/B7-H3-targeted antibody-drug conjugates with enhanced cancer-eradicating capability.
Feng Y; Lee J; Yang L; Hilton MB; Morris K; Seaman S; Edupuganti VVSR; Hsu KS; Dower C; Yu G; So D; Bajgain P; Zhu Z; Dimitrov DS; Patel NL; Robinson CM; Difilippantonio S; Dyba M; Corbel A; Basuli F; Swenson RE; Kalen JD; Suthe SR; Hussain M; Italia JS; Souders CA; Gao L; Schnermann MJ; St Croix B
Cell Rep; 2023 Dec; 42(12):113503. PubMed ID: 38019654
[TBL] [Abstract][Full Text] [Related]
26. A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.
Jeffrey SC; Burke PJ; Lyon RP; Meyer DW; Sussman D; Anderson M; Hunter JH; Leiske CI; Miyamoto JB; Nicholas ND; Okeley NM; Sanderson RJ; Stone IJ; Zeng W; Gregson SJ; Masterson L; Tiberghien AC; Howard PW; Thurston DE; Law CL; Senter PD
Bioconjug Chem; 2013 Jul; 24(7):1256-63. PubMed ID: 23808985
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral Payload Concentration Correlates with the Activity of Antibody-Drug Conjugates.
Zhang D; Yu SF; Khojasteh SC; Ma Y; Pillow TH; Sadowsky JD; Su D; Kozak KR; Xu K; Polson AG; Dragovich PS; Hop CECA
Mol Cancer Ther; 2018 Mar; 17(3):677-685. PubMed ID: 29348271
[TBL] [Abstract][Full Text] [Related]
28. Targeting CD19-positive lymphomas with the antibody-drug conjugate loncastuximab tesirine: preclinical evidence as single agent and in combination therapy.
Tarantelli C; Wald D; Munz N; Spriano F; Bruscaggin A; Cannas E; Cascione L; Gaudio E; Arribas AJ; Manjappa S; Golino G; Scalise L; Cacciapuoti MT; Zucca E; Stathis A; Inghirami G; Van Berkel PH; Rossi D; Caimi PF; Zammarchi F; Bertoni F
Haematologica; 2024 May; ():. PubMed ID: 38721745
[TBL] [Abstract][Full Text] [Related]
29. Antibody-Drug Conjugates with Indolinobenzodiazepine Dimer Payloads: DNA-Binding Mechanism of Indolinobenzodiazepine Dimer Catabolites in Target Cancer Cells.
Singh R; Reid EE; Harris L; Salomon PL; Miller ML; Chari RVJ; Keating TA
Mol Pharm; 2020 Jan; 17(1):50-58. PubMed ID: 31742408
[TBL] [Abstract][Full Text] [Related]
30. Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.
Hinrichs MJM; Ryan PM; Zheng B; Afif-Rider S; Yu XQ; Gunsior M; Zhong H; Harper J; Bezabeh B; Vashisht K; Rebelatto M; Reed M; Ryan PC; Breen S; Patel N; Chen C; Masterson L; Tiberghien A; Howard PW; Dimasi N; Dixit R
Clin Cancer Res; 2017 Oct; 23(19):5858-5868. PubMed ID: 28630216
[No Abstract] [Full Text] [Related]
31. Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.
White JB; Fleming R; Masterson L; Ruddle BT; Zhong H; Fazenbaker C; Strout P; Rosenthal K; Reed M; Muniz-Medina V; Howard P; Dixit R; Wu H; Hinrichs MJ; Gao C; Dimasi N
MAbs; 2019 Apr; 11(3):500-515. PubMed ID: 30835621
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate.
Vlahov IR; Qi L; Santhapuram HKR; Felten A; Parham GL; Zou N; Wang K; You F; Vaughn JF; Hahn SJ; Klein HF; Kleindl PJ; Reddy J; Reno D; Nicoson J; Leamon CP
Bioorg Med Chem Lett; 2020 Apr; 30(7):126987. PubMed ID: 32029324
[TBL] [Abstract][Full Text] [Related]
33. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity.
Zammarchi F; Havenith K; Bertelli F; Vijayakrishnan B; Chivers S; van Berkel PH
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912922
[TBL] [Abstract][Full Text] [Related]
34. Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Rios-Doria J; Harper J; Rothstein R; Wetzel L; Chesebrough J; Marrero A; Chen C; Strout P; Mulgrew K; McGlinchey K; Fleming R; Bezabeh B; Meekin J; Stewart D; Kennedy M; Martin P; Buchanan A; Dimasi N; Michelotti E; Hollingsworth R
Cancer Res; 2017 May; 77(10):2686-2698. PubMed ID: 28283653
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
36. Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody-Drug Conjugate.
Anderson MG; Falls HD; Mitten MJ; Oleksijew A; Vaidya KS; Boghaert ER; Gao W; Palma JP; Cao D; Chia PL; John T; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2020 Oct; 19(10):2117-2125. PubMed ID: 32847977
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.
Ryan MC; Palanca-Wessels MC; Schimpf B; Gordon KA; Kostner H; Meyer B; Yu C; Van Epps HA; Benjamin D
Blood; 2017 Nov; 130(18):2018-2026. PubMed ID: 28903943
[TBL] [Abstract][Full Text] [Related]
38. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.
Tiberghien AC; Levy JN; Masterson LA; Patel NV; Adams LR; Corbett S; Williams DG; Hartley JA; Howard PW
ACS Med Chem Lett; 2016 Nov; 7(11):983-987. PubMed ID: 27882195
[TBL] [Abstract][Full Text] [Related]
39. GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies.
Pascual-Pasto G; McIntyre B; Shraim R; Buongervino SN; Erbe AK; Zhelev DV; Sadirova S; Giudice AM; Martinez D; Garcia-Gerique L; Dimitrov DS; Sondel PM; Bosse KR
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460335
[TBL] [Abstract][Full Text] [Related]
40. Design and Synthesis of Isoquinolidinobenzodiazepine Dimers, a Novel Class of Antibody-Drug Conjugate Payload.
Smith SW; Jammalamadaka V; Borkin D; Zhu J; Degrado SJ; Lu J; Huang J; Jiang YP; Jain N; Junutula JR
ACS Med Chem Lett; 2018 Jan; 9(1):56-60. PubMed ID: 29348812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
